BACKGROUND: Optimal treatments for vulvar and vaginal melanomas (VVMs) have not been identified. Herein, the authors compare molecular profiles between VVM and nongynecologic melanoma (NGM) subtypes with the objective of identifying novel, targetable biomarkers. METHODS: In total, 2304 samples of malignant melanoma that were submitted to Caris Life Sciences between 2009 and 2015 were reviewed. In situ hybridization and immunohistochemistry were used to assess copy numbers and protein expression of selected genes. Sequenced variants were analyzed using a proprietary cancer panel. RESULTS: In total, 51 VVMs (14 vaginal and 37 vulvar melanomas) were compared with 2253 malignant NGMs, including 2127 cutaneous, 105 mucosal, and 21 acral melanomas. In VVMs, B-Raf proto-oncogene serine/threonine kinase (BRAF) was the most frequently mutated gene (26%) compared with 8.3% of mucosal NGMs (P 5.008). In BRAF-mutated tumors, fewer VVMs (50%), compared with NGMs (82.1%), had a variant within the valine codon 600 (V600) domain. The KIT mutation rate was highest in VVMs (22%) compared with 3% in cutaneous (P <.001) and 8.8% in mucosal (P 5.05) melanoma subtypes. NRAS mutations were rare in VVMs compared with cutaneous (25.9%; P 5.009) and acral (40.6%; P 5.002) melanoma subtypes. PD-L1 (56%) and PD-1 (75%) were frequently expressed in VVM, whereas PI3KCA pathway mutations and estrogen receptor/progesterone receptor expression were rare. Compared with VVMs that had KIT mutations, wildtype KIT VVMs were more likely to express molecular markers suggestive of platinum resistance (ERCC1), alkylating sensitivity (MGMT), and anthracycline sensitivity (TOP2A). CONCLUSIONS: The unique molecular features of VVM render this disease a distinct subtype of melanoma. Gene-based molecular therapy and immunotherapies may be promising and should be evaluated in clinical trials. Cancer 2017;123:1333-44. V C 2016 American Cancer Society.
INTRODUCTION
Primary melanoma of the female genital tract is rare, accounting for only 1% of all melanomas. 1 A recent Surveillance, Epidemiology, and End Results database study reported 1059 vulvar melanomas and 348 vaginal melanomas between 1973 and 2010. 2 Most melanomas arising from the female genital tract originate from the vulva (76%) and the vagina (19%). 1, 3 Compared with cutaneous and other types of mucosal nongynecologic melanoma (NGM), the overall prognosis for patients with vulvovaginal melanoma (VVM) is poor. The 5-year survival rate ranges from 58% for vulvar melanoma and 27% for vaginal melanoma, 2 whereas the 5-year survival rate for cutaneous melanoma can be as high as 81%. [4] [5] [6] Before the era of targeted molecular therapies, treatment options for VVM broadly included surgery, chemotherapy, and/or radiotherapy. 4, 7, 8 Unfortunately, because 40% of women with VVM reportedly present with regional or distant metastasis, 2 the late stage at diagnosis and high incidence of drug resistance 1 portend a poor prognosis. Differences in incidence, pathologic characteristics, and clinical outcomes among patients with VVM and other malignant melanoma subtypes are not well understood.
The molecular characterization of melanoma varies substantially across subtypes. In general, cutaneous melanomas not associated with chronic sun damage (CSD) harbor frequent mutations in B-Raf proto-oncogene serine/threonine kinase (BRAF), neuroblastoma rat sarcoma (NRAS), or other genes regulating cellular proliferation, apoptosis, and survival within the mitogen-activated protein (MAP) kinase pathway and the phosphatidylinositol-3 kinase/serine/threonine kinase (PI3K/AKT) pathway. 9 More recently, the KIT proto-oncogene receptor tyrosine kinase (KIT), a transmembrane receptor tyrosine kinase, reportedly was preferentially mutated in melanoma arising from mucosal, acral, or CSD surfaces (39%, 36%, 28%, respectively). 10, 11 It is difficult to extrapolate the current effectiveness of targeted therapies for cutaneous and mucosal melanomas to the treatment of diseases of other origins, such as tumors arising from the vulva and the vaginal tract.
Emerging treatments, such as immunotherapy and targeted molecular therapies, have achieved improved outcomes in patients with metastatic cutaneous melanoma. Historically, the response rates to dacarbazine, the approved first-line agent, have been low, ranging between 10% and 20%, and <5% of patients with melanoma achieve a complete response. 12 Other agents have been evaluated, including platinum/taxane, interleukin-2, and temozolomide (an oral analog of dacarbazine), and all have yielded similar low responses without survival benefit. 13 Recent US Food and Drug Administration (FDA) approval of ipilimumab (a monoclonal antibody that blocks cytotoxic T-lymphocyteassociated protein 4 [CTLA-4]), nivolumab and pembrolizumab (both checkpoint inhibitors that block programmed cell death 1 [PD-1] protein on cells), vemurafenib and dabrafenib (both BRAF inhibitors), as well as trametinib (a mitogen-activated protein kinase kinase [MEK] inhibitor) has expanded traditional chemotherapeutic options for treatment and significantly improved outcomes in patients with advanced-stage, unresectable melanoma. However, no specific clinical trials have validated the effectiveness of these agents in VVM.
Building on the existing literature, we hope to improve the current understanding of altered molecular pathways in VVM and thereby explore novel treatment options. Herein, we report the results from a comparative molecular analysis of 51 VVMs and 2253 NGMs.
MATERIALS AND METHODS

Patients and Multiplatform Molecular Profiling
This was an institutional review board-approved, retrospective review of 2304 consecutive malignant melanomas that were submitted from multiple institutions to a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (Caris Life Sciences, Phoenix, Ariz) for molecular profiling from 2009 through 2015. Hematoxylin and eosin-stained slides were reviewed by a boardcertified pathologist for sufficient tumor content and specimen quality and to verify the diagnosis on the pathology reports submitted with the tumor samples. Fifty-one melanomas of vulvar and vaginal origin (VVM) and 2253 melanomas of nongynecologic origin (NGMs) were confirmed. Multiplatform molecular analysis on each specimen included at least 1 platform: immunohistochemistry (IHC), in situ hybridization (ISH), or Sanger sequencing/ next-generation sequencing (NGS). Researchers were blinded from patient identifiers. Table 1 (see  online supporting information) . Appropriate positive and negative controls were used for all proteins tested. IHC analyses were scored manually by board-certified pathologists using predefined thresholds consisting of staining intensity (0, 11, 21, and 31) and the percentage of tumor cells that were stained positive. Thresholds were derived from the peer-reviewed clinical literature in which response to treatment was associated with biomarker status. Examples of positive and negative expression for the biomarkers of interest are included in Supporting Figure 1 (see online supporting information).
ISH
Gene copy number alterations in MET proto-oncogene receptor tyrosine kinase (c-MET), epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2) were analyzed by DNA ISH using fluorescence ISH (FISH) and/or chromogenic ISH (CISH) probes as part of the automated staining technique (Benchmark XT; Ventana Medical Systems) and the automated imaging system (BioView, Billerica, Mass). Cutoff scores are provided in Supporting Table 1 (see   Original Article online supporting information). Ratios higher than the defined cutoff were considered positive, and those less than the defined cutoff were considered negative.
Mutational Analysis: Sanger Sequencing
Sanger sequencing included selected regions of BRAF, KIT, EGFR, Kirsten rat sarcoma viral oncogene homolog (KRAS), NRAS, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) and was performed using M13-linked polymerase chain reaction (PCR) primers designed to flank and amplify targeted sequences. PCR products were bidirectionally sequenced using the BigDye Terminator cycle sequencing kit (version 1.1; Thermo Fisher Scientific, Waltham, Mass) and were analyzed using the 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY). Sequence traces were analyzed by 2 technologists, and results were confirmed by a board-certified clinical molecular geneticist using Mutation Surveyor software (version 3.25; Soft Genetics, State College, Pa). Additional sequencing and reference information is provided in Supporting Table 2 (see online supporting information).
Mutational Analysis: NGS NGS was performed on genomic DNA isolated from formalin-fixed, paraffin-embedded tumor tissue using the Illumina MiSeq platform. No DNA from matched normal tissue was sequenced. Specific regions of 47 genes were amplified using the Illumina TruSeq Amplicon Cancer Hotspot panel (Supporting Table 3 ; see online supporting information). All testing was validated and performed under accreditation from the CLIA, the College of American Pathologists, and International Organization for Standardization standard 15189 (2012). The average depth of coverage was >1500 base pairs, and all variants reported were detected with >99% confidence based on the mutation frequency present and the amplicon coverage. A 2-sided binomial calling model was used, and the calling threshold for mutation was 10% variant frequency, allowing for calling mutation and wild type (for the regions covered) at 99% confidence. The variants (mutations) analyzed included those that were scored as pathogenic, presumed pathogenic, or variant of unknown significance by board-certified molecular geneticists according to American College of Medical Genetics and Genomics standards and guidelines. 14 
Statistical Methods
A retrospective analysis of biomarker frequency distributions of interest in VVM and NGM (further classified into cutaneous, acral, and mucosal subtypes based on site of origin) was conducted using standard descriptive statistics. The Pearson chi-square test (IBM SPSS Statistics, version 23.0; IBM Corporation, Armonk, NY) was used to test for significant differences between subgroups, including a comparison of the incidence of BRAF, c-KIT, NRAS, and tumor protein 53 (TP53) mutations in melanomas of various locations and broadly classified as VVM and NGM. Two-tailed P values < .05 were considered statistically significant.
RESULTS
Clinical and Pathologic Characteristics
In total, 2304 malignant melanoma specimens were evaluated. The majority were cutaneous NGMs (NGM-cutaneous; n 5 2127), followed by mucosal NGMs (NGMmucosal; n 5 105), vulvar and vaginal melanomas (VVMs; n 5 51), and acral NGMs (NGM-acral; n 5 21). Of 51 VVMs, 37 originated from the vulva (72.5%), and 14 originated from the vagina (27.5%). The mean patient age did not differ between those with VVM (65 years) and those with NGM (63 years), and patients ranged in age from 19 to 66 years. Fifty-nine percent of VVMs occurred in postmenopausal women. Among all subgroups, significant numbers of samples were metastatic tumors, with the exception of the acral melanoma cohort. Table 1 summarizes the distribution of age and sex and the sites of origin in our melanoma cohort. Figure 1A summarizes the molecular alterations identified in the current cohort. The most common molecular changes in the NGM group were the expression of checkpoint protein PD-1 and its ligand PD-L1 (71.9% and 69.6%, respectively); followed by the expression of thymidylate synthase (TS), a protein correlated with outcomes for pemetrexed and 5-fluorouracil-based chemotherapy (63.4%); and b-tubulin isotype III (TUBB3), a marker associated with taxane resistance (63.1%). From a genomic perspective, BRAF mutations were the most common (34.4%) within the NGM cohort followed by NRAS (25.6%) and TP53 (17.3%) mutations.
Molecular Characteristics of VVM Are Distinct From Those of NGM
In contrast, the molecular markers most frequently expressed in the VVM group included topoisomerase IIa (TOP2A) (89%), PD-1 (75%), PD-L1 (56%), and phosphatase and tensin homolog (PTEN) (56%). Among the genes analyzed in VVM, BRAF was most frequently mutated (26%) followed by KIT (22%) and adenomatosis polyposis coli (APC) (10%). In addition to the most common molecular changes in the 2 groups, statistically significant differences in molecular markers of interest between VVM and NGM are listed in Table 2 .
It is widely accepted that the genomic characteristics of melanoma differ greatly by tissue of origin as well as association with CSD. 15 Seeking to elucidate the molecular features of VVM, we performed subgroup comparisons (Fig. 1B) to depict the frequency of molecular markers of interest among the NGM subtypes (cutaneous, mucosal, and acral) relative to VVM. The BRAF mutation rate varied significantly across subgroups, with the lowest rate observed in the NGM-acral subtype (P < .0001). Compared with the NGM-mucosal subtype, VVMs had significantly higher BRAF (26.1%; P 5 .008), and KIT (22.2%; P < .0001) mutation rates. Among NGMs, the acral (10.5%) and mucosal (8.8%) subtypes had much higher KIT mutation rates than the NGM-cutaneous subtype (3%). The frequency of NRAS mutation distribution also differed significantly among different melanoma subgroups. The NGM-acral subtype had the highest NRAS mutation rate (40.6%), whereas VVMs had the lowest mutation rate (4%). When considering molecular therapy, few options exist for patients who have tumors that do not harbor BRAF or KIT mutations. In the hope of identifying new, "actionable" biomarkers of interest, we performed subanalyses in our cohort stratified by BRAF and KIT mutation status (Table 3) .
The expression of TUBB3, a marker of taxane resistance, was more frequent in patients with BRAF-mutated VVM than in those with wild-type BRAF VVM (63% vs 0%; P 5 .04), suggesting that BRAF mutation may be a biomarker for taxane response specifically in the VVM cohort. In addition, mutations in BRCA2 (P 5 .04), NRAS (P 5 .0001), and KIT (P 5 .02) were significantly more common in wild-type BRAF than BRAF-mutated NGMs.
In the absence of KIT mutation, ERCC1 expression was significantly higher (P 5 .0002) and O-6-methylguanine-DNA methyltransferase (MGMT) expression was lower (P 5 .0004) in VVMs, suggesting preferential platinum resistance and possible sensitivity to alkylating agents like dacarbazine in this group compared with NGMs. 16 In addition, TOP2A, a marker of anthracycline sensitivity, 17 is more commonly expressed in wild-type KIT VVMs. In the NGM group, NRAS, BRAF, and catenin b1 are all significantly more likely to be mutated in tumors without KIT mutation. 6 distinct BRAF variants identified in VVMs, 50% (n 5 6) were valine-to-glutamic acid codon 600 (V600E) mutations, which are known as activating mutations that confer increased sensitivity to BRAF inhibitors. Of the remaining variants, 4 were inactivating mutations that may be associated with resistance to BRAF inhibitors, 18 and 1 was a variant (threonine residue 599 [T599]-V600E deletion) that has not been previously reported indicates AKT serine/threonine kinase 1; ALK, anaplastic lymphoma receptor tyrosine kinase; APC, adenomatosis polyposis coli; AR, androgen receptor; ATM, ATM serine threonine kinase; BCRP, breast cancer resistance protein; BRAF, v-raf murine sarcoma viral oncogene homolog B; BRCA1, breast cancer susceptibility gene 1; BRCA2, breast cancer susceptibility gene 2; CISH, chromogenic in situ hybridization; c-KIT, KIT proto-oncogene receptor tyrosine kinase; c-MET, MET proto-oncogene, receptor tyrosine kinase; CTNNB1, catenin b1; EGFR, epidermal growth factor receptor; ER, estrogen receptor; ERBB4, Erb-B2 receptor tyrosine kinase 4; ERCC1, ERCC excision repair 1, endonuclease noncatalytic subunit; FISH, fluorescence in situ hybridization; FLT3, Fms-like tyrosine kinase 3; GNA11, guanine nucleotide binding protein (G protein) a 11; GNAQ, guanine nucleotide binding protein G(q) subunit; GNAS, guanine nucleotide binding protein G(s) subunit; Her-2, human epidermal growth factor receptor 2; HNF1A, hepatic nuclear factor 1 a; IHC, immunohistochemistry; ISH, in sit hybridization; JAK2, Janus kinase 2; JAK3, Janus kinase 3; KDR, kinase insert domain receptor; KIT, KIT proto-oncogene receptor tyrosine kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, MET proto-oncogene, receptor tyrosine kinase; MGMT, O-6-methylguanine-DNA methyltransferase; MRP1, multidrug resistance-associated protein 1; mut, mutation; NRAS, neuroblastoma RAS viral oncogene homolog; PD-1, programmed cell death 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed cell death 1 ligand; PGP, phosphoglycolate phosphatase; PI3KCA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a; PR, progesterone receptor; PTEN, phosphatase and tensin homolog; RET, rearranged in transformation; RRM1, ribonucleotide reductase catalytic subunit M1; SMAD4, SMAD family member 4; SPARC, secreted protein acidic and cysteine rich; TLE3, transducing-like enhancing protein 3; TOP2A, topoisomerase (DNA) IIa; TOPO1, topoisomerase (DNA) 1; TP53, tumor protein 53; TS, thymidylate synthase; TUBB3, tubulin b3 class III;
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Cancer April 15, 2017 ( Fig. 3a) . The variant distribution in VVMs was distinct from that in NGMs. In NGMs, 66% were V600E mutations, and 82.1% of variants were within the V600 domain, which is associated with increased sensitivity to BRAF and/or MEK inhibitors (Fig. 3b) . The KIT mutation rate was highest in VVMs (22%). Forty percent of VVMs harbored a leucine-toproline substitution at codon 576 (L576P) variant in KIT (Fig. 3c) , which reportedly is a target of various KIT inhibitors; whereas 30% of its variants reportedly are associated with resistance to imatinib and/or sunitinib. In contrast, of the 24 KIT variants identified in NGMs (Fig.  3d) , 19% have been associated with drug resistance. We also report a previously unreported KIT variant (leucineto-arginine substitution at codon 576 [L576R]) with unknown clinical significance. NRAS mutation was rare in VVM (n 5 1). In contrast, of the 293 NRAS variants identified in NGMs, 97.6% were variants with reported sensitivity to sorafenib, a multikinase inhibitor, or to MEK inhibitors.
DISCUSSION
In recent years, there have been advances in understanding the molecular alterations that drive cutaneous melanoma, leading to the expansion of treatment options as well as improvements in survival. Although it has been demonstrated that mucosal melanoma is genetically distinct from melanoma arising from the skin and more commonly exhibits activating KIT and NRAS mutations, relatively little information is known about the molecular alterations that drive VVM. Herein, we report our results from a multiplatform molecular characterization across melanoma subtypes, including 1 of the largest cohorts of VVM in the literature. Our findings support the notion that VVM is a distinct entity from NGM overall and also from mucosal melanoma of other tumor origins, and these findings offer insights into future therapeutic options for these patients.
Molecular Targets
Our study is among the few examining BRAF mutations rates in VVM: 26% of VVMs harbored BRAF mutations compared with 36.6%, 8.3%, and 8.3% of cutaneous, mucosal, and acral melanomas, respectively. The distinct differences between our findings and published studies reporting on BRAF mutations in urogenital melanomas or VVMs warrant discussion. Table 4 is a comprehensive compilation of current studies and demonstrates that BRAF was mutated in 0% to 33% across sample sizes ranging from 1 to 39 patients with VVM. In the only VVM series to date larger than ours (39 vulvar and 15 vaginal melanomas), Aulmann et al reported no mutations in the BRAF gene. 19 Overall, of 416 patients with VVM who had known BRAF sequencing reported, 4.3% had a mutation.
It is unclear why our BRAF mutation rate (26%) was higher than that reported in literature for VVM. Although some of the earlier studies had smaller sample sizes, we doubt this alone could account for such discrepancy. An explanation may lie in the use of different mutation screening methods, which vary in sensitivity. Earlier PCR methods, such as single-strand conformational polymorphism analysis and conformation-sensitive gel electrophoresis, may miss 35% to 40% of mutations, respectively. 20 In our study, a combination of NGS (covering exons 1-18) and Sanger sequencing (covering exons 11 and 15) was used. In addition, many of our samples were metastatic and may have harbored mutations that differed from the molecular makeup of the primary tumor. In 1 study, when paired melanoma samples were analyzed, almost 50% had mutation patterns that differed between the primary and secondary tumors. 21 It is noteworthy that only 50% of the BRAF-mutant VVMs in our study harbored BRAF V600E mutations compared with 66% of the BRAF mutations identified in NGMs. A literature search of the remaining BRAF variants in VVM revealed possible inactivating mutations that were less likely to respond to vemurafenib, which is the FDA-approved selective inhibitor of the V600E-mutant BRAF kinase used to treat patients who have metastatic or unresectable melanoma with BRAF mutations. Our current results indicate that only 25% of VVMs harbor BRAF mutations and that only 50% of these mutations occur at V600E, which means that approximately 1 in every 8 patients with VVM can be treated with vemurafenib.
KIT plays a significant role in the oncogenesis of melanoma arising in mucosal membranes and acral skin, whereas non-CSD melanomas rarely harbor KIT mutations. 11 In our study, c-KIT mutations were observed in 22% of VVMs compared with 8.8% of mucosal NGMs. Our KIT mutation rate was comparable to published (Table 4) and unpublished data on VVM. 22 It is noteworthy that c-KIT was the only molecular marker of interest that varied significantly between vulvar and vaginal sites, with 27% of vulvar samples harboring the mutation compared with only 8% of vaginal samples. Our literature analysis demonstrated an overall KIT mutation rate of 31.4% in vulvar melanoma compared with 6.2% in its vaginal counterpart (Table 4) . This further highlights our conclusion that VVMs have a genetic profile that is distinct from that of mucosal melanomas, but this also raises the concept that vulvar melanoma may be associated with a much higher KIT mutation rate than vaginal melanoma. Of the 6 distinct c-KIT variants identified in the current study, 2 (an alanine-to-valine substitution at codon 736 [A736V] and a leucine-to-arginine substitution at codon 576 [L576R]) have unknown sensitivities to receptor tyrosine kinase inhibitors like imatinib, sunitinib, or sorafenib.
Immunotherapy Targets: CTLA-4 and PD-L1
Recent reports have associated the efficacy of BRAF and c-Kit inhibitors with antitumor T-cell responses. Targeted therapy against the MAP kinase pathway, such as vemurafenib, modulates the immune system in various ways. 23, 24 Progression-free survival in patients with PD-L1-positive tumors was as long as 14 months in those who received treatment with nivolumab, an immunoglobulin-G4 monoclonal antibody against PD-1. Even among patients who had PD-L1-negative tumors, when they received nivolumab combined with ipilimumab, their progressionfree survival improved. 25 In our study, PD-L1 (56%) and PD-1 (75%) were among the most frequently expressed molecular markers in VVM. With a known high rate of acquired resistance to c-KIT-targeted therapy reported in literature, high expression levels of PD-1 and PD-L1 in patients with VVM highlight the potential use of immunotherapy alone or in combination with targeted therapy for this disease.
It is worth noting that the lack of information on tumor mutation burden is a limitation of the current study.
Higher mutational burden is associated with improved response to PD-1 blockade. Although it is known that melanomas arising from ultraviolet radiation exposure have a much higher somatic mutation burden relative to other cancers, the extent of mutation also appears to be correlated with ultraviolet exposure. Both mucosal and acral melanomas reportedly harbor a lower mutation burden than cutaneous melanoma. Therefore, although the results from several phase 3 trials have supported the use of immunotherapy in metastatic melanoma, and combination trials of targeted therapy and immunotherapy are ongoing for BRAF-mutant melanoma, the generalizability of outcomes from those trials to patients with VVM is unknown and warrants further analysis 26, 27 .
Other Molecular Markers of Interest
Among our NGM samples, thymidylate synthase (TS) was expressed at higher levels compared with its expression in our VVM samples. TS inhibitors like 5-fluorouracil and pemetrexed have been approved as treatment for several malignancies, including nonsmall cell lung cancer, bladder cancer, colon cancer, and ovarian cancer. The antiproliferative effect of pemetrexed is markedly reduced in cells that overexpress TS, 28 suggesting resistance to TS inhibitors in melanoma. The molecular marker most frequently expressed in VVM was topoisomerase IIa (TOP2A), a protein that is the target of doxorubicin. In studies evaluating ovarian carcinoma, TOP2A gene gain and protein expression were associated with a higher clinical benefit in patients who received treatment with doxorubicin. 29 We observed that tubulin b3 (TUBB3) overexpression was significantly more frequent in patients with BRAF-mutated VVM than in those with wild-type VVM. The TUBB3 gene is an indicator of taxane resistance, because it is involved in a molecular pathway that promotes cell survival, which renders cancer cells resistant to apoptosis. This suggests that BRAF mutation may be a biomarker for taxane response specifically in patients with VVM, because TUBB3 expression does not follow a similar pattern in NGM. VVM is a rare disease. The strength of our study is rooted in its large sample size and its comprehensive representation of distinct subsets of melanoma, specifically 
